Key Takeaways
- In the 2025 financial year, 2.36 % of Australians aged 20‑65 filled at least one ADHD prescription, a figure close to the estimated adult prevalence of 2.5‑3 %.
- Prescription rates vary dramatically across the country, with some neighborhoods showing rates well above expected prevalence and others (so‑called “ADHD deserts”) falling below 0.5 %.
- Higher rates are generally found in more socio‑economically advantaged areas, but significant exceptions (e.g., Fremantle, Bassendean, Brunswick‑Coburg) indicate that income alone does not explain the pattern.
- Western Australia consistently records the highest dispensing rates; experts attribute this to a long‑standing culture of ADHD awareness and treatment, amplified recently by national tele‑health providers.
- In Victoria and New South Wales, the highest prescribing clusters appear in inner‑west and inner‑city suburbs rather than the wealthiest eastern corridors, suggesting that local service availability and community attitudes play a strong role.
- Areas with high disadvantage show very low prescription filling, implying that up to 90 % of adults with ADHD may be undiagnosed and untreated in those regions.
- Rising adult ADHD diagnoses coincide with the expansion of tele‑health clinics that offer rapid, questionnaire‑based assessments; concerns have been raised about the depth and reliability of some of these evaluations.
- Misdiagnosis can leave genuine psychiatric conditions (e.g., mood, personality, trauma disorders) untreated, while unnecessary stimulant exposure carries risks of hypertension, anxiety, insomnia, weight loss, and rare psychotic episodes.
- Clinicians report an anecdotal increase in psychosis presentations linked to stimulant use, prompting calls for more rigorous diagnostic standards and better monitoring of medication safety.
- Policy efforts to train GPs to diagnose and prescribe ADHD aim to improve access, but current Medicare reimbursement may limit bulk‑billing viability, potentially reintroducing cost barriers.
- The data underscore a pressing need for national scrutiny: improving equitable access, ensuring diagnostic rigor, and balancing treatment benefits against harms.
National ADHD prescription prevalence
The analysis of Pharmaceutical Benefits Scheme data shows that in the 2025 financial year, 2.36 % of adults aged 20‑65 received at least one ADHD medication dispensing. This proportion sits just below the epidemiologic estimate that 2.5‑3 % of adults truly have ADHD, suggesting that overall prescribing is roughly aligned with expected prevalence when viewed nationally. However, the national figure masks substantial heterogeneity at the local level, where some communities far exceed the anticipated rate while others lag far behind.
Geographic variation and mapping
When prescription rates are mapped by Statistical Area 3 (SA3), a striking pattern emerges: darker shades indicate higher dispensing, and the contrast between the darkest and lightest zones is stark. In the highest‑prescribing SA3s, the proportion of adults filling scripts can be more than double the national average, whereas in the lowest‑prescribing areas the figure falls below 0.4 %. This wide spread translates into what researchers describe as “ADHD hotspots” and “ADHD deserts,” highlighting that diagnosis and treatment are not uniformly distributed across Australia.
Socio‑economic advantage and its limits
An initial hypothesis linked higher prescribing to greater socioeconomic advantage, based on the notion that assessment and treatment can cost thousands of dollars. Plotting prescription rates against the Index of Relative Socio‑economic Disadvantage (IRSD) indeed shows a general trend: more advantaged deciles tend to have higher dispensing. Yet the relationship is far from perfect. Neighborhoods such as Fremantle in Western Australia, Bassendean, and Bunbury sit well above the expected prevalence despite not being in the top income deciles, while some affluent suburbs record only modest rates. These outliers indicate that factors beyond income—such as local service culture, awareness campaigns, and provider availability—play a substantive role.
Western Australia as an outlier
Western Australia consistently tops the national charts for ADHD prescribing, hosting 13 of the 20 highest‑dispensing SA3s. Dr Kyle Hoath, president of the AMA’s WA branch, notes that WA has historically maintained higher rates of ADHD treatment in both children and adults than the eastern states. He attributes the current lead to a legacy of awareness that has kept WA proportionally ahead as national diagnosis rates rise. The state’s relatively low psychiatrist‑to‑population ratio further complicates the picture, suggesting that many prescriptions may originate from interstate tele‑health services rather than local specialists.
State‑level patterns: Victoria, NSW
In Victoria, the highest prescription concentrations appear in Brunswick, Coburg, and Darebin South—inner‑west suburbs known for diverse populations and active community health networks—rather than the traditionally affluent eastern suburbs. A similar pattern emerges in New South Wales, where the Marrickville, Sydenham, and Petersham area of Sydney’s inner west, along with the Blue Mountains, show the strongest dispensing rates. These findings reinforce the idea that local service provision, advocacy groups, and perhaps cultural attitudes toward mental health influence diagnosis more than simple wealth gradients.
ADHD deserts and missed diagnosis
At the opposite end of the spectrum, disadvantaged localities such as Fairfield in south‑west Sydney exhibit prescription filling rates of just 0.3 %, a mere fraction of the expected 2.5‑3 % prevalence. Assuming the true prevalence holds, this implies that up to 90 % of adults with ADHD in Fairfield may be undiagnosed and untreated. Such “ADHD deserts” are concentrated in areas with high IRSD scores, limited private‑psychiatry access, and fewer community mental‑health resources, pointing to a significant equity gap in care.
Role of awareness, social media, and telehealth
The surge in adult ADHD diagnoses parallels the rise of social‑media discourse wherein users share symptom checklists and personal narratives, prompting self‑referral for assessment. Concurrently, tele‑health clinics specialising in ADHD have proliferated, offering rapid, often questionnaire‑based evaluations that can be completed from home. These services have improved access for many, especially in underserved regions, but they also raise questions about diagnostic thoroughness.
Quality and concerns about telehealth assessments
Clinicians such as Professor David Gohill and clinical psychologist David Bakker have voiced reservations about the depth of some tele‑health reports. Assessments that rely solely on symptom checklists without comprehensive clinical interviews, collateral information, or consideration of differential diagnoses may produce “rubber‑stamp” conclusions. While many patients report positive experiences, others describe feeling rushed or insufficiently explored, suggesting variable quality across providers.
Risks of misdiagnosis and medication harms
An incorrect ADHD diagnosis can obscure coexisting conditions—mood disorders, personality disorders, trauma‑related sequelae—that require different therapeutic approaches. Stimulant medications, the mainstay of ADHD treatment, are not innocuous; side effects include elevated blood pressure, tachycardia, anxiety, insomnia, and appetite suppression. Though rare, cases of stimulant‑induced psychosis have been noted anecdotally by emergency physicians across multiple states, who report a noticeable rise in presentations among patients prescribed amphetamines.
Psychosis concerns and clinician observations
Jacqueline Huber, an emergency psychiatrist at St Vincent’s Hospital, told Four Corners that the proportion of psychosis cases linked to recent stimulant use has increased, even if hard data are still lacking. Danielle McMullen, federal president of the AMA, echoed these concerns, warning that psychostimulants carry genuine risks and that adverse events can be severe. Simultaneously, untreated ADHD is associated with higher rates of substance‑use disorders, accidents, and broader functional impairment, underscoring that both over‑ and under‑treatment carry public‑health costs.
Public health implications and policy responses
The data reveal a paradox: while some communities enjoy relatively abundant access to ADHD assessment and treatment, others are left with minimal services despite comparable need. Recent policy moves aim to train general practitioners to diagnose and prescribe ADHD, hoping to bridge the gap. However, the current Medicare reimbursement framework may not adequately remunerate lengthy ADHD assessments under bulk billing, potentially preserving cost barriers for low‑income patients. Without addressing financing, workforce distribution, and diagnostic rigor, efforts to expand GP‑based care could inadvertently exacerbate inequities or increase reliance on low‑quality tele‑health services.
Conclusion and need for scrutiny
The nationwide analysis of ADHD prescribing uncovers a complex tapestry of over‑diagnosis in certain affluent or service‑rich locales and profound under‑diagnosis in disadvantaged areas. Socio‑economic advantage explains part of the variation, but local awareness, provider availability, and the rapid expansion of tele‑health also shape patterns. Misdiagnosis risks leaving genuine psychiatric illness untreated, while unnecessary stimulant exposure poses measurable health hazards. Moving forward, Australia must pursue a balanced strategy: enhance equitable access to specialist care, ensure assessments are thorough and guideline‑consistent, monitor medication safety rigorously, and refine funding models so that cost does not become a barrier to appropriate treatment. Only through such multifaceted scrutiny can the nation hope to meet the true needs of adults living with ADHD while minimizing harm.